Keybanc Reiterates Buy Rating on ResMed Inc. with $266 Target
Keybanc has maintained its buy rating on ResMed Inc., setting a price target of $266, a 35.37% upside from the current price.
Key Points
- Keybanc reiterated its buy rating for ResMed Inc. (RMD) with a price target of $266 on June 22, 2026.
- Keybanc's $266 price target implies 35.37% upside from ResMed Inc.'s ($RMD) current $196.50 share price.
- RMD shares traded at $188.63 on Monday, with a market cap of $27.36 billion and a P/E ratio of 18.19.
- Insiders at ResMed, including CEO Michael Farrell, have been active in trading, with several transactions reported in June 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Keybanc has reiterated its buy rating on ResMed Inc. (NYSE:RMD), setting a price target of $266. This update came on June 22, 2026, from analyst Justin Patterson. ResMed's shares traded around $188.63 on Monday.
Keybanc vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
ResMed Inc. Stock Down 18.2%
Shares of NYSE:RMD traded at approximately $188.63 on Monday. ResMed Inc. has a market capitalization of around $27.36 billion. The company sports a price-to-earnings (P/E) ratio of 18.19 and a forward P/E of 15.58. Its beta is 0.782, indicating lower volatility compared to the market. Over the past 52 weeks, the stock has ranged from $180.27 to $293.81. The 50-day moving average stands at $207.07, while the 200-day moving average is $242.57. The company maintains a current ratio of 3.01 and a quick ratio of 2.00, with a debt-to-equity ratio of 12.99.
$RMD price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
ResMed reported revenue of approximately $5.54 billion, reflecting a growth of 10.8%. The net margin is 27.44%, and the return on equity (ROE) is 25.25%. The company earned $10.37 per share. ResMed is scheduled to announce its next earnings on August 6, 2026.
Dividend
ResMed pays an annual dividend rate of $2.40, yielding 1.27%. The dividend payout ratio is 22.47%.
Insider Buying and Selling at ResMed Inc.
Insider activity at ResMed Inc. has been notable. On June 8, 2026, CEO Michael Farrell executed several transactions, selling 4,991 shares at prices ranging from $0 to $193.96, with some transactions planned under Rule 10b5-1. Additionally, Farrell purchased 4,991 shares at $146.34 without a pre-planned arrangement. Global General Counsel Michael Rider sold 269 shares at $190.57 on June 1, 2026.
Analysts Set New Price Targets
On June 22, 2026, Keybanc maintained its buy rating for ResMed with a price target of $266. Earlier, on June 17, Morgan Stanley downgraded the stock to a hold rating with a $230 target. Citigroup also maintained a buy rating with a $270 target on June 15. Overall, the consensus among analysts is a buy, with an average price target of $262.20 based on 15 opinions.
About ResMed Inc.
ResMed Inc. is a healthcare company based in San Diego, California. It develops and markets medical devices and cloud-based software applications to diagnose and manage respiratory disorders. The company operates in segments such as Sleep and Breathing Health and Residential Care Software. Led by CEO Michael J. Farrell, ResMed employs 10,600 people and provides solutions like sleep recorders and cloud-based patient management systems.
Bottom Line
Keybanc's decision to maintain a buy rating on ResMed Inc. with a $266 target highlights ongoing analyst confidence in the company. ResMed's shares, which traded near $188.63, reflect its solid market presence with a significant market cap and steady earnings growth. Investors keep a close eye on analyst ratings and insider transactions for insights into the company's future performance.
Get ResMed Inc. alerts
New 13F filings, insider trades, and analyst moves on $RMD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.